Ivermectin, a potential anticancer drug derived from an antiparasitic drug

Abstract

Ivermectin is a macrolide antiparasitic drug with a 16-membered ring that is widely used for the treatment of many parasitic diseases such as river blindness, elephantiasis and scabies. Satoshi ōmura and William C. Campbell won the 2015 Nobel Prize in Physiology or Medicine for the discovery of the excellent efficacy of ivermectin against parasitic diseases. Recently, ivermectin has been reported to inhibit the proliferation of several tumor cells by regulating multiple signaling pathways. This suggests that ivermectin may be an anticancer drug with great potential. Here, we reviewed the related mechanisms by which ivermectin inhibited the development of different cancers and promoted programmed cell death and discussed the prospects for the clinical application of ivermectin as an anticancer drug for neoplasm therapy.

Keywords: avermectin(PubChem CID：6434889); cancer; doramectin(PubChem CID：9832750); drug repositioning; ivermectin; ivermectin(PubChem CID：6321424); moxidectin(PubChem CID：9832912); selamectin(PubChem CID：9578507).